Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrvinium for Gastric Intestinal Metaplasia
NCT06590454Phase 2Recruiting
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in gastric intestinal metaplasia (IM) comparing Pyrvinium with Placebo (2 arms). Primary endpoint: Change in the number of clinical biopsies with evidence of gastric intestinal metaplasia. Started Dec 2025; status: recruiting.
02
Drugs
pyrvinium
03
Conditions
gastric intestinal metaplasia (IM)
Beyond the preview
Go deeper on NCT06590454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06590454.